NEW YORK, July 15, 2024 /PRNewswire/ -- A recent survey by MedFluencers has highlighted a significant shift in how healthcare professionals (HCPs) are turning to social media for pharmaceutical education and patient engagement. MedFluencers, an HCP influencer marketing agency founded by physicians, surveyed HCPs across 15 specialties, revealing insights into their interactions with pharmaceutical and medical device companies on social media.
Travere Therapeutics management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 ...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA...
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the...
ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ?1.0 g/day (or urine protein-to-creatinine ratio ?0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Travere to present abstracts at SIMD and GMDI highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for HCU